Fabrication of carbon film composites for high-strength structures

Physical and mechanical properties of fiber composite materials consisting of carbon films are described. Application of carbon film structural composites for constructing microwave filters or optical instruments is proposed. Applications in aerospace and architectural structures for high strength and low density properties are discussed

Physical properties of thin films

Studies and experiments are presented on carbon, boron, aluminum oxide, zirconium silicate, aluminum, and titanium vapor-deposited on polyimide film substrates

Large diameter astromast development, phase 1

Coilable-longeron lattice columns called Astromasts (trademark) were manufactured for a variety of spacecraft missions. These flight structures varied in diameter from 0.2 to 0.5 meter (9 to 19 in.), and the longest Astromast of this type deploys to a length of 30 meters (100 feet). A double-laced diagonal Astromast design referred to as the Supermast (trademark) which, because it has shorter baylengths than an Astromast, is approximately four times as strong. The longeron cross section and composite material selection for these structures are limited by the maximum strain associated with stowage and deployment. As a result, future requirements for deployable columns with high stiffness and strength require the development of both structures in larger diameters. The design, development, and manufacture of a 6.1-m-long (20-ft), 0.75-m-diameter (30-in.), double-laced diagonal version of the Astromast is described

Axisymmetric and cylindrical isostabiloids

Differential equations for compression loaded axisymmetric cylindrical structure

Axisymmetric filamentary structures

Axisymmetric filamentary structure

Extravehicular activity translation arm (EVATA) study

The preliminary design of a deployable Extravehicular Activity Translation Arm (EVATA) assembly which will allow an EVA crewman to perform tasks in the vicinity of the External TNK (ET) umbilical doors and to inspect most of the underside of the shuttle spacecraft is reported. The concept chosen for the boom structure was the Astro Extendable Support Structure (ESS) which formed the main structure for the Synthetic Aperture Radar (SAR) Antenna System on the SEASAT A spacecraft. This structure is a deployable triangular truss. A comparison of the EVATA and the SEASAT A ESS is shown. The development of status of the ESS is shown. The satellite configuration, the stowed truss load path, and the envelope deployment sequence for the ESS are also shown

Spoked wheels to deploy large surfaces in space-weight estimates for solar arrays

Extensible booms were used to deploy and support solar cell arrays of varying areas. Solar cell array systems were built with one or two booms to deploy and tension a blanket with attached cells and bussing. A segmented and hinged rim supported by spokes joined to a common hub is described. This structure can be compactly packaged and deployed

Installing hydrolytic activity into a completely <i>de novo </i>protein framework

The design of enzyme-like catalysts tests our understanding of sequence-to-structure/function relationships in proteins. Here we install hydrolytic activity predictably into a completely de novo and thermostable α-helical barrel, which comprises seven helices arranged around an accessible channel. We show that the lumen of the barrel accepts 21 mutations to functional polar residues. The resulting variant, which has cysteine–histidine–glutamic acid triads on each helix, hydrolyses p-nitrophenyl acetate with catalytic efficiencies that match the most-efficient redesigned hydrolases based on natural protein scaffolds. This is the first report of a functional catalytic triad engineered into a de novo protein framework. The flexibility of our system also allows the facile incorporation of unnatural side chains to improve activity and probe the catalytic mechanism. Such a predictable and robust construction of truly de novo biocatalysts holds promise for applications in chemical and biochemical synthesis

Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection

Background. Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants (MVs) are present in some antiretroviral therapy (ART)-naive patients. They may result from de novo mutagenesis or transmission. To date, the latter has not been proven. Methods. MVs were quantified by allele-specific polymerase chain reaction in 204 acute or recent seroconverters from the Zurich Primary HIV Infection study and 382 ART-naive, chronically infected patients. Phylogenetic analyses identified transmission clusters. Results. Three lines of evidence were observed in support of transmission of MVs. First, potential transmitters were identified for 12 of 16 acute or recent seroconverters harboring M184V MVs. These variants were also detected in plasma and/or peripheral blood mononuclear cells at the estimated time of transmission in 3 of 4 potential transmitters who experienced virological failure accompanied by the selection of the M184V mutation before transmission. Second, prevalence between MVs harboring the frequent mutation M184V and the particularly uncommon integrase mutation N155H differed highly significantly in acute or recent seroconverters (8.2% vs 0.5%; P < .001). Third, the prevalence of less-fit M184V MVs is significantly higher in acutely or recently than in chronically HIV-1-infected patients (8.2% vs 2.5%; P = .004). Conclusions. Drug-resistant HIV-1 MVs can be transmitted. To what extent the origin—transmission vs sporadic appearance—of these variants determines their impact on ART needs to be further explore

Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.

BACKGROUND: Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants (MVs) are present in some antiretroviral therapy (ART)-naive patients. They may result from de novo mutagenesis or transmission. To date, the latter has not been proven. METHODS: MVs were quantified by allele-specific polymerase chain reaction in 204 acute or recent seroconverters from the Zurich Primary HIV Infection study and 382 ART-naive, chronically infected patients. Phylogenetic analyses identified transmission clusters. RESULTS: Three lines of evidence were observed in support of transmission of MVs. First, potential transmitters were identified for 12 of 16 acute or recent seroconverters harboring M184V MVs. These variants were also detected in plasma and/or peripheral blood mononuclear cells at the estimated time of transmission in 3 of 4 potential transmitters who experienced virological failure accompanied by the selection of the M184V mutation before transmission. Second, prevalence between MVs harboring the frequent mutation M184V and the particularly uncommon integrase mutation N155H differed highly significantly in acute or recent seroconverters (8.2% vs 0.5%; P &lt; .001). Third, the prevalence of less-fit M184V MVs is significantly higher in acutely or recently than in chronically HIV-1-infected patients (8.2% vs 2.5%; P = .004). CONCLUSIONS: Drug-resistant HIV-1 MVs can be transmitted. To what extent the origin-transmission vs sporadic appearance-of these variants determines their impact on ART needs to be further explored